Core Insights - Esperion Therapeutics reported a loss of 21 cents per share in Q1 2025, which was wider than the Zacks Consensus Estimate of a loss of 18 cents, compared to earnings of 34 cents per share in the same quarter last year [1] - Total revenues for Esperion in Q1 2025 were $65 million, reflecting a 53% year-over-year decline, primarily due to a one-time milestone payment received in Q1 2024; however, revenues exceeded the Zacks Consensus Estimate of $58 million [2] - The company's stock fell 7.1% on May 6 following the earnings announcement and has decreased 55.7% year-to-date, contrasting with a 0.4% decline in the industry [3] Financial Performance - Product revenues from the U.S. totaled $34.9 million in Q1 2025, up 41% year-over-year, driven by expanded label and commercial initiatives; this figure surpassed the Zacks Consensus Estimate of $29.8 million [5] - Collaboration revenues, including royalties and partner revenues, were $30.1 million, down almost 73% year-over-year, but beat the Zacks Consensus Estimate of $27.9 million [8] - Research and development expenses decreased by 6% to $12.6 million, while selling, general, and administrative expenses rose by 2% to $43 million due to increased marketing and consulting costs [8][9] Future Outlook - Esperion expects operating expenses for 2025 to be in the range of $215-$235 million, which includes $15 million in non-cash expenses related to stock compensation [10] - The company is developing two triple combination products with Nexletol/Nexlizet, expected to launch in 2027, which may offer LDL-C lowering of more than 60% [11] - Esperion is also planning to develop ESP-1336 for the treatment of primary sclerosing cholangitis (PSC), a market estimated to exceed $1 billion annually [12]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 grew 63% year over year to $65 million after adjusting for a one-time milestone received in Q1 2024 [9][19] - U.S. net product revenue increased 41% year over year to $34.9 million, driven by expanded label and commercial initiatives [9][20] - Collaboration revenue decreased approximately 73% to $30.1 million due to the settlement agreement milestone, but grew 97% excluding that milestone [20][22] Business Line Data and Key Metrics Changes - U.S. product sales growth was impacted by seasonal headwinds and changes in Medicare Part D, but early Q2 trends show prescription volume tracking approximately 8% higher than Q1 [9][21] - The company expanded its field reimbursement support team threefold to enhance access for prescribers [9][10] - The inclusion of NEXLETOL and NEXLASET in the 2025 ACCAHA guidelines is expected to improve market access and prescribing behavior [10][11] Market Data and Key Metrics Changes - Royalty revenue from Daiichi Sankyo Europe increased 8% from Q4 2024 to $10.5 million in Q1 2025, with approximately 472,500 patients treated in Europe [14][15] - The Japanese market is anticipated to be a significant revenue contributor, with approval expected in the second half of 2025 [16] Company Strategy and Development Direction - The company is focused on revenue growth, portfolio expansion, and pipeline advancement, particularly in cardiovascular health [6][7] - Plans to commercialize a triple combination product by 2027, which aims to provide a compelling option for LDL cholesterol management [13][17] - The company is expanding its global reach through partnerships and regulatory submissions in various international markets [16][17] Management Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by seasonal market dynamics and changes in Medicare, but expressed optimism about a return to growth [21][62] - The company is committed to navigating complexities in the healthcare landscape to ensure patient access to its products [21][22] - Management emphasized the importance of innovation and collaboration in driving future growth and improving cardiovascular health [24] Other Important Information - The company reiterated its full-year 2025 operating expense guidance of approximately $215 million to $235 million [23] - Cash and cash equivalents stood at $114.6 million as of March 31, 2025, indicating a strong financial position [23] Q&A Session Summary Question: When should we expect a new business development deal? - Management is making progress but will not set a timeline for a new deal, as they want to ensure it aligns with the company's strategy [30][31] Question: Is the triple combination product a defensive strategy? - The triple combination product is seen as a convenient option for patients, potentially offering the most efficacious LDL lowering treatment on the market [32][33] Question: Is the current sales force right-sized? - The current sales force of approximately 155 representatives is deemed appropriate, with a focus on balancing personal and digital promotion [39] Question: What are the dynamics affecting NEXLETOL and NEXLIZET sales? - Seasonal factors and confusion around Medicare impacted sales, but early signs of improvement are noted as patient co-pays decrease [62][63] Question: What is the timeline for the triple combination product? - The product is expected to reach the market in 2027, with no clinical study required for regulatory approval [67] Question: What is the outlook for gross margin? - Gross margin is expected to improve as the tech transfer progresses, with adjustments in cost of goods sold anticipated to stabilize [70][71]

Core Insights - Esperion Therapeutics reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, and a decline from earnings of $0.34 per share a year ago, indicating an earnings surprise of -16.67% [1] - The company generated revenues of $65 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 12.58%, but down from $137.74 million year-over-year [2] - Esperion's shares have declined approximately 52.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] Earnings Outlook - The future performance of Esperion's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [4][5] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $64.91 million, and for the current fiscal year, it is -$0.09 on revenues of $338.51 million [7] Industry Context - The Medical - Drugs industry, to which Esperion belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Metagenomi, is expected to report a quarterly loss of $0.62 per share, reflecting a year-over-year change of +47.9%, with revenues anticipated to be $8.75 million, down 21.6% from the previous year [9]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 grew 63% year over year to $65 million after adjusting for a one-time milestone received in Q1 2024 [7][19] - U.S. net product revenue increased 41% year over year to $34.9 million, driven by expanded label and commercial initiatives [7][19] - Collaboration revenue decreased approximately 73% to $30.1 million due to the settlement agreement milestone with DSE, but grew 97% excluding that milestone [21] Business Line Data and Key Metrics Changes - U.S. product sales growth was impacted by a flat lipid market and seasonal headwinds, with script growth increasing only 2% sequentially compared to Q4 2024 [7][20] - The market access team achieved significant milestones, including the removal of prior authorizations for over 30 plans, enhancing access for patients [8][10] - The company expanded its field reimbursement support team threefold to 15 specialists, improving support for prescribers [7][38] Market Data and Key Metrics Changes - The company reported that approximately 472,500 patients have been treated with its therapies in Europe, with royalty revenue from DSE increasing 8% from Q4 2024 to $10.5 million in Q1 2025 [13][14] - The Japanese market is expected to be a significant contributor, with approval for bempedoic acid anticipated in the second half of 2025 [14] Company Strategy and Development Direction - The company is focused on revenue growth, portfolio expansion, and pipeline advancement, with a commitment to improving cardiovascular health [5][23] - A new triple combination product is being developed, expected to provide significant LDL cholesterol reduction and is projected for commercialization in 2027 [12][62] - The company aims to leverage its leadership in ACLY biology and expand into high-need indications, such as primary sclerosing cholangitis (PSC) [16] Management's Comments on Operating Environment and Future Outlook - Management noted that the first quarter faced challenges due to changes in Medicare Part D and higher out-of-pocket costs, but early Q2 trends show prescription volume tracking approximately 8% higher than Q1 [20][58] - The management expressed confidence in the strategic initiatives to drive growth and improve patient access to innovative therapies [23][24] Other Important Information - The company reiterated its full-year 2025 operating expense guidance of approximately $215 million to $235 million, including $15 million in non-cash expenses related to stock compensation [22] - The company is actively pursuing new business development opportunities and is not waiting for specific milestones to execute deals [29] Q&A Session Summary Question: When should we expect a new business development deal? - Management is making good progress but will not set a timeline for a deal, as they want to ensure it makes sense for the company [29] Question: Is the triple combination a defensive strategy? - The triple combination is seen as a convenient option for patients, potentially being the most efficacious LDL-lowering drug on the market [31] Question: Is the sales force right-sized? - The current sales force of approximately 155 representatives is deemed appropriate, balancing personal and digital promotion [37] Question: How is the company addressing physician education on statin intolerance? - The company is focusing on educating physicians about statin intolerance, with significant traction in messaging about the unmet need for patients who cannot tolerate statins [40] Question: What is the gross margin trajectory? - Gross margin is influenced by the sales mix between U.S. and partner sales, with expectations for improvement as tech transfer progresses [65]

Exhibit 99.1 – Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – Esperion Reports First Quarter 2025 Financial Results – Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., May 6, 2025 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today reported financial results for the first quarte ...

Financial Performance - Total revenue reached $65 million, reflecting a 63% increase adjusting for a one-time settlement agreement milestone received in Q1 2024[9] - U S net product sales grew by 41% to $34 9 million[10] - Collaboration revenue was $30 1 million[34] Prescription Trends - Q1 2025 script growth increased by 2% compared to Q4 2024[15, 16] - Early Q2 2025 prescription volume is tracking approximately 8% higher than Q1 2025[16] Market Access and Clinical Validation - The company tripled the U S field reimbursement team to 15 specialists[12] - Over 30 major healthcare plans removed prior authorizations and expanded formulary coverage for NEXLETOL and NEXLIZET[12] Global Expansion - Products are approved in 40 countries globally[21] - Approximately 472,500 patients have been reached internationally through February 2025[24] Pipeline Development - The company is developing a triple combination product with an estimated LDL-C reduction of approximately 60%-70%[19] - A program targeting Primary Sclerosing Cholangitis (PSC) is in development, with an IND planned for 2026, addressing a market opportunity estimated at over $1 billion annually[27, 30]

Core Insights - Esperion reported Q1 2025 total revenue of $65.0 million, a decrease of 53% year-over-year, but adjusted for a one-time milestone in Q1 2024, total revenue grew 63% year-over-year [1][15] - U.S. net product revenue increased by 41% year-over-year to $34.9 million [1][15] - Bempedoic acid received Level 1a recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines for managing patients with Acute Coronary Syndromes [1][10] - The company expanded its development portfolio with a new program targeting Primary Sclerosing Cholangitis (PSC), a market estimated to exceed $1 billion [1][3] Financial Performance - Total revenue for Q1 2025 was $65.0 million, down from $137.7 million in Q1 2024, primarily due to a settlement agreement milestone received in the previous year [15][33] - U.S. net product revenue rose to $34.9 million from $24.8 million in the same period last year, marking a 41% increase [15][33] - Collaboration revenue fell to $30.1 million from $113.0 million year-over-year, a decrease of 73%, but grew 97% when excluding the milestone [15][33] - The company reported a net loss of $40.5 million compared to a net income of $61.0 million in Q1 2024 [13][33] Commercial Strategy - The company surpassed one million prescriptions for bempedoic acid products in the U.S. [3][6] - Esperion expanded its reimbursement team from five to 15 specialists to enhance support for healthcare providers and patients [6] - New marketing initiatives targeting statin-intolerant patients, who represent 30% of the lipid-lowering market, are expected to drive prescription growth [6][3] - The company is advancing two triple combination products for commercialization in 2027, which could provide LDL-C lowering in excess of 60% [6][3] Research and Development - Esperion hosted an R&D Day highlighting its capabilities and promising research for PSC treatment candidates [10][7] - Pre-clinical data showed that the company's allosteric ACLY inhibitor could reduce liver injury markers in PSC models [10][7] - The estimated prevalence of diagnosed PSC patients in the U.S. and Europe is approximately 76,000 as of 2024 [10][7] Market Positioning - Esperion's European partner, Daiichi Sankyo Europe, reported an 8% sequential increase in royalty revenue to $10.5 million, indicating strong market penetration for its products [10][6] - The company is on track for expected approval and pricing in Japan in the second half of 2025 [6][10]

ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsper ...

Welcome to R&D Day April 24, 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, plans for potential future product candidates, fin ...

"We are leveraging our deep expertise in ACLY biology to expand our portfolio beyond NEXLETOL (bempedoic acid)/NEXLIZET (bempedoic acid and ezetimibe) and to address the urgent needs of patients living with PSC," said Sheldon Koenig, Chief Executive Officer at Esperion. "Our lead candidates, including ESP- 1336, are promising, potential first-in-class allosteric ACLY inhibitors, well-characterized with significant preclinical data, and represent a natural extension of our metabolic franchise. PSC is a rare ...